Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study

Status

Terminated

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03606070

Acronym

IMAHTEP

Enrollment

Registered

2018-07-30

Start date

2017-11-25

Completion date

2019-08-29

Last updated

2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Brief summary

To estimate the intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping in locally advanced and trace mestastatic non-small cell lung cancer (NSCLC).

Interventions

DIAGNOSTIC_TESTPET-MRI

* a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI) * a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Locally advanced NSCLC (stages IIB, IIIA or IIIB of the TNM classification 7th edition) or trace metastatic stage IV (\</=5 mestastasis, \</= 3 organ reached) 2. Exclusive therapeutic management by concomitant radio-chemotherapy administered in accordance with international recommendations (dual therapy with platinum salts) 3. Signed consent 4. Patients affiliated with the social security scheme or beneficiary of a similar scheme.

Exclusion criteria

1. Minor 2. Pregnant / lactating woman 3. Person deprived of liberty by judicial or administrative decision, adults who are the subject of a legal protection measure or unable to express their consent 4. Previous cancer in the 2 years prior to registration 5. Previousradiotherapy / thoracic surgery 6. Patients under experimental treatment or for whom the administration of an experimental treatment is planned 7. Claustrophobic patients 8. Severe Renal Insufficiency (Clearance MDRD Cockroft \<30ml / min) 9. Uncontrolled diabetes, hyperglycemia\> 1.8g / L 10. Patient with metallic implants not compatible with MRI or any immovable implanted electronic medical device (eg pacemaker, neurostimulator, cochlear implants, etc.)

Design outcomes

Primary

Measure	Time frame
Measurement of intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping performed before and under treatment.	Up to 24 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026